Pfizer Inc. (NYSE:PFE) finished Thursday with an addition of $0.53 to close at $51.33, an upside of 1.04 percent. An average of 11,309,860 shares of common stock have been traded in the last five days. There was a fall of -$0.33 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 20,588,230 shares traded, while the 50-day average volume stands at 21,120,773.
PFE stock has increased by 3.72% in the last month. The company shares reached their 1-month lowest point of $49.04 on 11/30/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $41.44 and a high of $59.80 in 52 weeks. It has reached a new high 1 time so far this year and lost -13.07% or -$7.72 in price. In spite of this, the price is down -14.16% from the 52-week high.
PFE stock investors should be aware that Pfizer Inc. (PFE) stock had its last reported insider trading activity 206 days ago on Jun 07. In this transaction, the insider spent $227,603. SVP & Controller, DAMICO JENNIFER B., disposed of 4,000 shares at a price of $50.50 on May 16. The insider now owns more than $202,000 worth of shares. Prior to that, Executive Vice President SAHNI PAYAL went on to Sale 1,408 shares at $49.84 each on May 13. An amount of $70,175 was transacted.
Pfizer Inc. (PFE) has a trailing price-to-earnings (P/E) ratio of 9.74. The stock’s beta is 0.66. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.88, the price-to-book (PB) ratio at 3.11, and the price-to-cash flow ratio at 19.88.
The company has a payout ratio of 29.90%. The company’s most recent quarterly dividend payment was $0.41 a share, representing a up of 2.5% from $0.40 last year. Its latest increase dividend $0.01 reported on Friday December 9 2022.
The quick ratio of Pfizer Inc. for the three months ended September 29 was 1.40, and the current ratio was 1.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.35 and a total debt to equity ratio of 0.40 for the quarter ending September 29. Its gross profit as reported stood at $50.47 billion compared to revenue of $81.29 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Pfizer Inc.’s return on assets was 15.80%.
For the three-month period that ended September 29, Pfizer Inc. had $34.83 billion in cash and short-term investments compared to $32.63 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $8.61 billion in the quarter, while revenues of $9.91 billion were grew 5.37%. The analyst consensus anticipated Pfizer Inc.’s latest quarter earnings to come in at $1.39 per share, but it turned out to be $1.78, a 28.10% surprise. For the quarter, EBITDA amounted to $10.13 billion. Shareholders own equity worth $5.61 billion.
From a technical analysis perspective, let’s take a brief look at Pfizer Inc. (PFE) price momentum. RSI 9-day as of the close on 29 December was 50.39%, suggesting the stock is Neutral, with historical volatility in this time frame at 23.06%.
As of today, PFE’s price is $51.35 -0.64% or -$0.33 from its 5-day moving average. PFE is currently trading +2.39% higher than its 20-day SMA and +3.55% higher than its 100-day SMA. However, the stock’s current price level is +16.42% above the SMA50 and -1.69% below the SMA200.
The stochastic %K and %D were 19.17% and 29.44%, respectively, and the average true range (ATR) was 1.03. With the 14-day stochastic at 14.99% and the average true range at 1.06, the RSI (14) stands at 53.99%. The stock has reached -0.30 on the 9-day MACD Oscillator while the 14-day reading was at -0.88.
Goldman upgraded Pfizer Inc. (NYSE: PFE) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Pfizer Inc. (PFE) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PFE, while 10 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 12 others rate it as a “buy”.
What is PFE’s price target for the next 12 months?
Analysts predict a range of price targets between $44.00 and $75.00, with a median target of $54.00. Taking a look at these predictions, the average price target given by analysts for Pfizer Inc. (PFE) stock is $55.35.